News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Direxion Expands Single Stock Leveraged & Inverse ETF Lineup for Exposure to Eli Lilly & Palo Alto Networks

Direxion

Direxion, a pioneer in Single Stock Leveraged and Inverse ETFs, expanded its suite of high-powered trading tools with the launch of four new funds tracking the performance of Eli Lilly and Company (LLY) and Palo Alto Networks, Inc. (PANW). These funds provide traders with amplified, or inverse, exposure to two of the most dynamic sectors – pharmaceuticals and cybersecurity – through the Direxion Daily LLY Bull 2X Shares (Ticker: ELIL) and Direxion Daily LLY Bear 1X Shares (Ticker: ELIS), or the Direxion Daily PANW Bull 2X Shares (Ticker: PALU) and Direxion Daily PANW Bear 1X Shares (Ticker: PALD). “These new ETFs give active traders an edge, whether they want to double down on momentum, or hedge against volatility, in two industry-leading stocks,” said Douglas Yones, CEO of Direxion. “Eli Lilly’s innovation in healthcare, and Palo Alto Networks’ in cybersecurity, make them prime candidates for our growing suite of tactical trading tools. We remain committed to launching new ETF solutions for short-term traders, with more to come in the near future." As ground-breaking products built for active traders, Direxion’s pairs of single stock leveraged and inverse ETFs are meant to be used for short-term trading purposes. Leveraged and inverse single stock ETFs should not be viewed as buy and hold investments, but rather trading tools for traders with a high-risk tolerance. In addition, unlike traditional ETFs, or even other levered and/or inverse ETFs, these ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. All Direxion leveraged and inverse ETFs are intended only for investors with an in-depth understanding of the risks associated with seeking leveraged investment results, and who plan to actively monitor and manage their positions. There is no guarantee these ETFs will meet their objective. Please visit the Direxion Leveraged and Inverse ETF Education Center, where you will find educational brochures, videos, and a self-paced online course to help you understand if leveraged and inverse ETFs – including single stock ETFs – are right for you. About Direxion: Direxion equips investors who are driven by conviction with ETF solutions built for purpose and fine-tuned for precision. These solutions are available for a broad spectrum of investors, whether executing short-term tactical trades, or investing in thematic strategies. Direxion’s reputation is founded on developing products that precisely express market perspectives and allow investors to manage their risk exposure. Founded in 1997, the company has approximately $47.0 billion in assets under management as of December 31, 2024. For more information, please visit www.direxion.com. There is no guarantee that the Funds will achieve their investment objectives. For more information on all Direxion Shares ETFs, go to www.direxion.com, or call us at 866.301.9214. An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a prospectus and summary prospectus call 866.476.7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing. Investing in the funds involves a high degree of risk. Unlike traditional ETFs, or even other leveraged and/or inverse ETFs, these leveraged and/or inverse single-stock ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. Leveraged and inverse ETFs pursue daily leveraged investment objectives, which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying stock’s performance over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments. The Funds will lose money if the underlying stock’s performance is flat, and it is possible that the Bull Fund will lose money even if the underlying stock’s performance increases, and the Bear Fund will lose money even if the underlying stock’s performance decreases, over a period longer than a single day. Investing in the Funds is not equivalent to investing directly in LLY or PANW. Direxion Shares Risks – An investment in a Fund involves risk, including the possible loss of principal. Each Fund is non-diversified and includes risks associated with a Fund concentrating its investments in a particular security, industry, sector, or geographic region which can result in increased volatility. A Fund's investments in derivatives such as futures contracts and swaps may pose risks in addition to, and greater than, those associated with directly investing in securities or other investments, including imperfect correlations with underlying investments or the Fund's other portfolio holdings, higher price volatility and lack of availability. As a result, the value of an investment in a Fund may change quickly and without warning. Leverage Risk – The Bull Fund obtains investment exposure in excess of its net assets by utilizing leverage and may lose more money in market conditions that are adverse to its investment objective than a fund that does not utilize leverage. A total loss may occur in a single day. Leverage will also have the effect of magnifying any differences in the Fund’s correlation with LLY or PANW and may increase the volatility of the Bull Fund. Daily Correlation Risk - A number of factors may affect the Bull Fund’s ability to achieve a high degree of correlation with LLY or PANW and therefore achieve its daily leveraged investment objective. The Bull Fund’s exposure to LLY or PANW is impacted by LLY or PANW’s movement. Because of this, it is unlikely that the Bull Fund will be perfectly exposed to LLY or PANW at the end of each day. The possibility of the Bull Fund being materially over- or under-exposed to LLY or PANW increases on days when LLY or PANW is volatile near the close of the trading day. Daily Inverse Correlation Risk - A number of factors may affect the Bear Fund’s ability to achieve a high degree of inverse correlation with LLY or PANW and therefore achieve its daily inverse investment objective. The Bear Fund’s exposure to LLY or PANW is impacted by LLY or PANW’s movement. Because of this, it is unlikely that the Bear Fund will be perfectly exposed to LLY or PANW at the end of each day. The possibility of the Bear Fund being materially over- or under-exposed to LLY or PANW increases on days when LLY or PANW is volatile near the close of the trading day. Eli Lilly and Company Investing Risk – Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. Eli Lilly and Company faces risks associated with: costly and uncertain research and development of its products; maintaining intellectual property protections; intense competition from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers; increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for its drugs; the development of safety or efficacy concerns; among other risks.. Pharmaceutical Industry Risk – The profitability of pharmaceutical companies is highly dependent on the development, procurement and marketing of drugs and the development, protection and exploitation of intellectual property rights and other proprietary information. These companies may be significantly affected by the expiration of patents or the loss of, or the inability to enforce, intellectual property rights. Healthcare Sector Risk — Companies in the healthcare sector may be affected by extensive, costly and uncertain government regulation, rising costs of medical products and services, changes in the demand for medical products and services, an increased emphasis on outpatient services, limited product lines, industry innovation and/or consolidation, changes in technologies and other market developments. Palo Alto Networks, Inc. Investing Risk – Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. Palo Alto Networks, Inc. faces risks associated with: development of new products and services may be difficult; may be unable to attract new customers; reliance on channel partners; credit and liquidity risk of customers; sales to government entities may be subject to greater scrutiny; intense competition; among other risks. Information Technology Sector Risk — The value of stocks of information technology companies and companies that rely heavily on technology is particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation, and competition, both domestically and internationally, including competition from competitors with lower production cost. Additional risks of each Fund include Effects of Compounding and Market Volatility Risk, Derivatives Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Industry Concentration Risk, Market Risk, Indirect Investment Risk, and Cash Transaction Risk. Additionally, for the Direxion Daily LLY Bear 1X Shares and Direxion Daily PANW Bear 1X Shares, Shorting or Inverse Risk. Please see the summary and full prospectuses for a more complete description of these and other risks of a Fund. Distributor: ALPS Distributors, Inc. Contact Details Ditto Public Relations Danielle Black, AD direxion@dittopr.co Company Website https://www.direxion.com/

March 26, 2025 09:00 AM Eastern Daylight Time

Article thumbnail News Release

XVesuvius Named Men's Health "Best Acne Product"

XVolcano

XVolcano's flagship product, XVesuvius, has been named the Men's Health 2025 Grooming Award Winner for "Best Acne Product," recognizing its innovative approach to treating acne with a proprietary combination of clinical-strength active ingredients. “Out of all the acne products our testers tried, they said this one was most effective at attacking active breakouts. One application in the morning and one at night was all it took to erase zits in as little as a day,” said Men’s Health. This prestigious honor acknowledges XVesuvius's effectiveness, particularly for athletes and active individuals dealing with stubborn acne. "We're thrilled to receive this recognition from Men's Health," said Steve Dworman, Founder of XVolcano. "XVesuvius was developed to address multiple aspects of skin health with clinical-strength ingredients. Our formula was created to not only clear acne but to improve overall skin health through clinically-validated ingredients that target multiple pathways simultaneously." XVesuvius represents a breakthrough in skincare through its innovative combination of clinically-validated ingredients at full clinical strength. Based on research shared by board-certified dermatologists, XVesuvius delivers comprehensive skin transformation through seven key mechanisms: - Advanced Antimicrobial Activity Without Antibiotics - Superior Hydration Technology - Powerful Anti-Inflammatory Properties - Sebum Regulation - Advanced Anti-Scarring Technology - Hyperpigmentation Reduction - Comprehensive Anti-Aging Effects "What makes XVesuvius truly revolutionary is its comprehensive approach to skin health," noted Dr. Serena Mraz, a board-certified, Stanford-trained dermatologist who has evaluated the product. "The formula contains a rich combination of potent ingredients that address multiple components of acne, acne sequelae, and aging changes with skin health-boosting effects. Most skincare regimens require 4-5 different products to achieve what XVesuvius accomplishes in one formula." About XVolcano XVolcano is dedicated to developing innovative skincare solutions that address specific challenges faced by athletes and active individuals. The company's flagship product, XVesuvius, combines cutting-edge skincare science with practical formulations designed for real-world use. For more information, visit www.xvolcano.com. Contact Details Farrington PR Kim Farrington kim@farringtonpr.com Company Website https://xvolcano.com/

March 20, 2025 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Market Alert: Inspira Technology Gains Industry Exposure as FDA-Cleared Technology Showcased at Major Conference

Global Markets News

Market News Alerts Reports: Inspira Technologies (NASDAQ: IINN)* is gaining attention today as their FDA-cleared INSPIRA™ ART100 life-support system is being showcased at the prestigious AmSECT International Conference in San Diego, potentially exposing their technology to hundreds of perfusion professionals. This high-profile exhibition comes at a strategic moment for Inspira, with recent developments showing momentum: The FDA-cleared INSPIRA ART100 system is being prepared for deployment in leading U.S. hospitals Recent clinical studies demonstrated 96% accuracy for their HYLA blood sensor technology The company is advancing development of their flagship INSPIRA ART500 system With the company visionairy approach targeting approximately 20 million ICU patients with acute respiratory failure annually worldwide, Inspira aims to address significant markets: the $5.7B blood gas analyzer market and the $19B mechanical ventilation sector. The company's approach allows patients to remain awake during treatment without ventilators—addressing a need where current solutions face significant challenges. This conference appearance raises Inspira's profile within the perfusion community, potentially supporting their commercialization strategy as they work to introduce their technology to medical institutions. * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published Market News Alerts Research, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. Contact Details Markets News Alerts Editorial Desk globalmarkets.media@gmail.com

March 19, 2025 11:28 AM Eastern Daylight Time

Article thumbnail News Release

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

Global Markets News

NeuroSense's Groundbreaking ALS Combination Therapy PrimeC Advances Towards commercialization in Canada potential for revenue in canada alone of $100-150 million dollars. PrimeC Has Previously Demonstrated Unprecedentedly Strong Clinical Efficacy; Market News Alerts Reports -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Compliance/conditional (NOC/c) regulatory pathway for PrimeC as a treatment for Amyotrophic Lateral Sclerosis (ALS). NeuroSense is targeting potential approval in Canada by H1 2026. The company estimates peak annual revenue potential of $100-150M USD in the Canadian market. This meeting marks a critical step in NeuroSense's regulatory strategy for PrimeC PrimeC is NeuroSense's lead drug candidate for ALS, a novel extended-release oral formulation combining ciprofloxacin and celecoxib. The drug has demonstrated promising results in clinical trials, including the Phase 2b PARADIGM study, which showed a 36% reduction in disease progression and 43% improvement in survival rates compared to placebo. In December 2024, NeuroSense reported positive FDA feedback on its Phase 3 trial design for PrimeC, with plans to initiate the pivotal study in mid-2025. The company has also announced entering a binding term sheet with a global pharmaceutical company to advance PrimeC's development, which includes substantial upfront payments and funding for the Phase 3 program. This Canadian regulatory development represents a potential pathway to earlier commercialization while the larger Phase 3 program proceeds for global markets. The neurodegenerative disease treatment market has witnessed transformative licensing deals that highlight the immense value of innovative therapies. GlaxoSmithKline's 2021 collaboration with Alector set a remarkable precedent with a $700 million upfront payment and potential milestone payments of $1.5 billion, while the Biogen and Denali Therapeutics partnership in 2020 involved $560 million upfront and potential milestones approaching $1.125 billion. These deals underscore the pharmaceutical industry's willingness to invest heavily in breakthrough neurological innovations, potentially like NeuroSense's PrimeC. Some Wall Street Analysts reportedly maintain a Buy Rating for NeuroSense with AGP giving the company a $7.50 price target representing a significant premium over current Prices; * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution is paid promotional content related to NeuroSense Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by NeuroSense Therapeutics prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we it endorse them, they are quoted based on publicly available news reports and additional or price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details Market News Alerts Editorial Desk globalmarkets.media@gmail.com

March 19, 2025 11:01 AM Eastern Daylight Time

Article thumbnail News Release

Cortland Biomedical Expands Braiding Capabilities with New Flat and Round-Flat-Round Braiders to Drive Medical Device Innovation

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of custom engineering services, has expanded its braiding capabilities with the addition of flat braiding and round-flat-round braiding equipment. This latest investment provides Cortland Biomedical’s OEM customers with access to a full suite of braiding technologies, further strengthening the company’s position as a trusted partner enabling less invasive medical devices across a range of surgical applications. Braids plays a critical role in the design and performance of implantable medical textiles, particularly for orthopedic and sports medicine applications such as tendon and ligament repair. Flat braiding enables precise control over width and thickness, offering enhanced customization for applications requiring flexible yet strong structures that are able to distribute and bear force effectively. Meanwhile, round-flat-round braiding allows for seamless transitions between different braid geometries, optimizing load distribution and mechanical properties essential for next-generation medical devices. This unique structure enables a needle to be attached to the round section or tip, providing additional functionality. “With the addition of these new braiders, we are expanding the design possibilities for our customers, giving them even greater flexibility in developing high-performance biomedical textiles,” said Wesley Conger, engineering director, Cortland Biomedical. “This investment underscores our commitment to delivering custom textile solutions that meet the evolving needs of the medical device industry.” The expanded capabilities complement Cortland Biomedical’s existing expertise in braiding – which already included low and high density braiding, and branch braiding -- as well as woven, knitted, and other advanced textile engineering solutions. By offering a comprehensive range of biomedical textile technologies, the company continues to support OEMs in accelerating innovation and improving patient outcomes. About Cortland Biomedical Cortland Biomedical – which is now FDA registered -- custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

March 19, 2025 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Centre For Neuro Skills to Open Clinic in Plano; Fifth in Texas

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of treatment for traumatic and acquired brain injury, today announced the opening of its new clinic in Plano, Texas. CNS’ approximately 20,000 square ft. facility at 1649 Dallas Parkway will open to new patients in winter 2025-2026. “Over the past few years, we’ve seen population growth in the North Dallas area, with Plano being one of the fastest growing regions,” said David Harrington, CEO of CNS. “We are increasing our footprint in Texas to meet the high demand for our facilities and individualized services to bring high-quality post-acute care to not only North Texas but also neighboring states like Oklahoma.” Patient-centered approach to treating brain injury CNS, highly regarded for its expertise in brain injury and stroke treatment as well as its experienced staff. Three of CNS’ clinics, including one in Irving, recently received accreditation by the Behavioral Health Center of Excellence for demonstrating its commitment to the standards of excellence for applied behavior analysis services. As CNS’ fifth Texas location, the Plano clinic will deepen the post-acute care provider’s commitment to the Dallas Healthcare community and the state. CNS’ Plano location’s many advanced-care features include: Programs for vision, neurobehavior, cognitive retraining, speech, physical and occupational therapy provided by highly trained and certified clinical therapy staff The ZeroG® Gait and Balance System Bioness Integrated Therapy System (BITS), used to aid in vision, motor and balance training Individualized counseling as well as family counseling (a hallmark of CNS support) Opportunities to participate in cutting edge brain injury and stroke research Brain injury and its devastating and costly effects Traumatic brain injury (TBI) is caused by blunt, traumatic forces to the brain. Acquired Brain Injury (ABI) is a non-traumatic brain injury or disease such as stroke, encephalitis or other infectious diseases, anoxic/hypoxic injury (lack of oxygen to the brain), aneurysms, seizure disorders, surgical procedures and toxic exposure. According to the Brain Injury Association of America, 2.9 million Americans visit the emergency department due to a TBI every year. According to the Texas Brain Injury Alliance: 144,000 Texans sustain a TBI each year — one every 4 minutes More than 381,000 Texans live with a disability due to a TBI — 2% of the population More than 5,700 Texas residents are permanently disabled by TBI each year Convenient Location CNS’ new clinic offers space to accommodate a broader population of inpatient, outpatient, day treatment and residential post-acute brain injury patients. It is adjacent to the Dallas North Tollway and located minutes from area airports and hotels. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 13, 2025 08:01 AM Pacific Daylight Time

Article thumbnail News Release

Spring Bird Welcomes Thomas Hoskins as New Director of Operations

Spring Bird

Spring Bird, a leading provider of innovative transit solutions, is pleased to announce the appointment of Thomas Hoskins as its new Director of Operations. With more than two decades of experience in transit operations, fleet management, and manufacturing process improvement, Thomas will play a critical role in optimizing Spring Bird’s operational strategy and driving continued growth. Thomas brings a wealth of expertise to his new role, having served eight years as Director of Operations at Complete Coach Works, where he led fleet modernization efforts and oversaw large-scale production improvements. His career also includes 13 years as an Operations Manager at Motor Coach Industries, where he gained extensive experience managing complex transit manufacturing and service operations. “Spring Bird is growing rapidly, and having an experienced, forward-thinking leader like Thomas at the helm of our operations is part of our long-term growth strategy,” said Elliott Carson, CEO and Founder of Spring Bird. “Tom’s history of driving efficiency and innovation aligns perfectly with our mission to provide safe, high-quality transit solutions. We are excited for his leadership and enhance will drive our operational excellence and benefit our customers.” In his new role, Thomas will oversee production processes, fleet operations, and strategic planning, ensuring that Spring Bird continues to meet and exceed industry standards. His leadership will support the company’s ongoing efforts to expand its offerings, enhance efficiency, and deliver reliable, sustainable transit solutions. “I am honored to join Spring Bird at such a pivotal time in its growth,” said Thomas Hoskins, Director of Operations. “The company’s commitment to quality, innovation, and customer service is truly inspiring. I look forward to working with the team to refine processes, improve efficiency, and continue delivering exceptional transit solutions that keep our customers moving.” Spring Bird, founded in 2020, builds upon the Carson family’s decades-long legacy in the transit industry, offering a wide range of heavy-duty transit buses and rehabilitation services. The company services the industry's top operators, providing buses for sale and lease, and specializes in minor repairs, major overhauls, and operational maintenance solutions. With Thomas at the helm of operations, Spring Bird is well-positioned to continue its expansion and commitment to excellence in transit solutions. About Spring Bird Spring Bird is a premier provider of transportation solutions, specializing in the sale, leasing, and service of heavy-duty transit buses and motor coaches. Drawing from the rich Carson family legacy in the transportation industry, Spring Bird offers an inventory of high-quality buses from leading manufacturers and provides customized rehabilitation services, including minor repairs, major overhauls, and technological retrofitting. Dedicated to safety, innovation, and customer satisfaction, Spring Bird addresses the unique needs of cities, transit agencies, and private operators, ensuring reliable and efficient transportation solutions. Media Contact: For more information, visit https://springbirdbus.com or contact us at press@springbirdbus.com. ### About Spring BirdSpring Bird is a premier provider of transportation solutions specializing in the sale, leasing, and service of heavy-duty transit buses and motor coaches. Drawing from the rich Carson family legacy in the transportation industry, Spring Bird offers an inventory of high-quality buses from leading manufacturers and provides customized rehabilitation services, including minor repairs, major overhauls, and technological retrofitting. Dedicated to safety, innovation, and customer satisfaction, Spring Bird addresses the unique needs of cities, transit agencies, and private operators, ensuring reliable and efficient transportation solutions. Contact Details Media Contact press@springbirdbus.com Company Website https://springbirdbus.com

March 12, 2025 09:00 AM Central Daylight Time

Image
Article thumbnail News Release

Centre for Neuro Skills Launches its First Advertising Campaign

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, has launched the company’s first advertising campaign in its 45-year history. The initial campaign, “Rethink Rehab,” is aimed at medical decision-makers, prospective patients and their families and will roll out across video digital platforms, social media and out-of-home advertising, bringing a fresh and engaging message to consumers. Designed to raise awareness of the CNS brand, its services and its impact, the campaign features dramatic, dark visuals that end on an inspiring note of hope for all that are recovering from brain injury or stroke. The campaign’s theme, “Rethink Rehab,” captures the essence of CNS’ mission to reduce disability and maximize independence, reinforcing its commitment to achieve the maximum quality of life for patients through brain injury rehabilitation. "With 'Rethink Rehab,' we’re redefining how we connect with our audience,” said Ben Ashley, Associate Vice President Marketing and Communications for CNS. "Through this multichannel campaign, we aim to raise awareness of the CNS brand, our services, and our impact within both professional and cultural contexts. We recognize that our audience is diverse and that our influence extends to medical decisions, countless patients and their families. Our ultimate goal is to increase access to our care by spreading knowledge about CNS, even before it is needed. This campaign embodies our brand’s passion for neurorehabilitation and brings it to life in an authentic, compelling way.” CNS employs a unique and individualized treatment approach that is transforming the understanding of effective neurorehabilitation programs for individuals recovering from brain injury and stroke. The creative agency behind the campaign is Moon Rabbit, an independent advertising agency with offices in New York, California and London. Their clients range from boutique to blue-chip and from consumer to biotech. CNS’ partnership with Moon Rabbit has enabled them to highlight this impact through a 30-second spot. The video begins with an inspiring journey of a mother as she perseveres through her brain injury recovery. It concludes on a positive note as she successfully regains control of her daily tasks and family life. Throughout her journey, our experienced and compassionate staff are there to guide her every step of the way. “‘Neurorehabilitation’ is a word only learned after a life gets fundamentally shaken. And yet, too often, the conversation in this space can feel detached & mechanical,” said John Tenaglia, Managing Partner, Client Services at Moon Rabbit. “Just as CNS brings humanity to their process, we aim to bring humanity to the conversation around what rehabilitation & recovery really look like.” This short film is just one component of our exciting new multichannel advertising campaign with Moon Rabbit, which includes digital banners, out-of-home promotions, social media placements, radio spots, and published advertorials. Key highlights of the campaign include: Multi-Platform Reach – The campaign will launch across social media, digital streaming, and radio and unique activations. Engaging Storytelling – The video begins with an inspiring journey of a mother as she perseveres through her brain injury recovery. It concludes on a positive note as she successfully regains control of her daily tasks and family life. Throughout her journey, our experienced and compassionate staff are there to guide her every step of the way. The campaign officially debuted on February 1, 2025. Consumers can follow the conversation using #[RethinkRehab] and view campaign content at www.neuroskills.com, Facebook, Twitter, LinkedIn or YouTube. For media inquiries, interviews, images or additional information, please contact: Robin Carr Landis Communications Inc. 415.766.0927 CNS@landispr.com *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 10, 2025 08:01 AM Pacific Daylight Time

Image
Article thumbnail News Release

Centre for Neuro Skills Launches the “Neuro Skills Podcast,” Focused on Brain Injury Rehabilitation

Centre for Neuro Skills

The Centre for Neuro Skills (CNS) has launched the “Neuro Skills Podcast,” a new series that delves into the latest trends, research and inspiring stories behind the transformative power of brain injury rehabilitation. Debuting on YouTube and Spotify on Monday, March 3, in recognition of Brain Injury Awareness Month, this weekly video series features real-life recovery stories and expert insights on cutting-edge brain injury therapies. The podcast aims to deepen understanding of brain injury rehabilitation and its life-changing possibilities. Hosted by CNS CEO and President David Harrington—a licensed occupational therapist and Certified Brain Injury Specialist with more than 30 years of experience—the podcast will feature conversations with industry leaders, brain injury survivors and experts in post-acute rehabilitation. Notable guests include CNS founder Dr. Mark Ashley and key figures in neurorehabilitation, who will share their expertise and personal experiences. “Brain injury rehabilitation is a journey of resilience, innovation and hope. Through the ‘Neuro Skills Podcast,’ we aim to shed light on groundbreaking therapies, share real recovery stories and provide valuable insights from experts in the field,” says David Harrington, President and CEO of Centre for Neuro Skills and podcast host. “Our goal is to empower patients, families and healthcare professionals with the knowledge and inspiration they need to navigate the path to healing.” Episodes: Episode 1 (available now): A Place of Healing: The Story of CNS When Dr. Mark Ashley’s brother, Steve, became disabled after a devastating event in 1972, conventional rehabilitation therapy gave no hope for recovery. Dr. Ashley, Founder of CNS, made it his mission to find a way for Steve to regain his independence through post-acute rehabilitative care. His recovery became the model for CNS’ ongoing philosophy of practice and our belief that patients don’t plateau, and every brain injury survivor deserves a place to heal and regain independence. Episode 2 (March 10, 2025): Heart Health is Brain Health Pt. 1 Most people don’t know that strokes are brain injuries. This episode explores the connection between heart health and brain health – an often-overlooked aspect of stroke prevention and recovery. Tune in as David Harrington, President and Chief Executive Officer of CNS, and Chris Persel, Regional Director of Clinical Services, Director of Behavior Programming at CNS, dive into key statistics, discuss stroke prevention methods, and explain treatment options that help stroke survivors rebuild their lives and regain independence. Episode 3 (March 17, 2025): Heart Health is Brain Health Pt. 2 Recovery from a brain injury is a lifelong personal journey. David Harrington, President and Chief Executive Officer of CNS, and Chris Persel, Regional Director of Clinical Services, Director of Behavior Programming at CNS, continue their discussion on the importance of engaging patients in rehabilitation through individualized treatments and enriched environments. Episode 4 (March 24): Resilience and Renewal After a Brain Injury How do emotions impact recovery? David Harrington, President and Chief Executive Officer of CNS, and Dr. Gary Seale, Regional Director of Clinical Services at CNS, talk about the significant role that positive emotions play in patient recovery. This episode explores the benefits of being in a positive emotional state: ability to process information quickly and accurately, boost to the immune system, and there’s a less likely chance to trigger the flight or fight response that can lead to risk factors for stroke. Episode 5 (March 31): A Doctor Becomes the Patient: Stroke Survivor Story An unexpected stroke not only impacted Dr. Petersen’s motor skills, but it also changed the way he views the patient experience. A loving father with a background in pediatric emergency medicine, Dr. Petersen overcame physical, emotional, and cognitive deficits during his stroke rehabilitation journey, finding a renewed sense of purpose when he returned to work. In this episode, Dr. Petersen shares his journey from physician to patient and sheds light on the transformative power of rehabilitation. Produced in collaboration with the American Heart Association (AHA) as part of its “Live Fierce campaign,” the “Neuro Skills Podcast” reflects CNS’s commitment to advancing neurorehabilitation and heart health. Through this partnership, CNS and the AHA aim to provide critical information to stroke patients and the broader community, reinforcing the connection between brain health and cardiovascular well-being. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 06, 2025 08:01 AM Pacific Standard Time

Image
12345 ... 310